Assessment of Mortality in Autoimmune Myositis With and Without Associated Interstitial Lung Disease

Lung

Volumn 194, Issue 5, 2016, Pages 733-737

  Johnson, Cheilonda ^a   Pinal Fernandez, Iago ^b   Parikh, Radhika ^c   Paik, Julie ^a   Albayda, Jemima ^a   Mammen, Andrew L ^a,b   Christopher Stine, Lisa ^a   Danoff, Sonye ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^c UNIVERSITY OF VERMONT   (United States)

Author keywords

Clinically amyopathic dermatomyositis; Dermatomyositis; Idiopathic inflammatory myopathy; Interstitial lung disease; Polymyositis; Survival

Indexed keywords

AUTOANTIBODY;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ASSESSMENT; CLINICALLY AMYOPATHIC DERMATOMYOSITIS; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DERMATOMYOSITIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MORTALITY RATE; MYOSITIS; POLYMYOSITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; UNITED STATES; AGED; COMPLICATION; EPIDEMIOLOGY; LUNG DIFFUSION CAPACITY; PATHOPHYSIOLOGY; TOTAL LUNG CAPACITY;

ADULT; AGED; AUTOIMMUNE DISEASES; CROSS-SECTIONAL STUDIES; DERMATOMYOSITIS; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PULMONARY DIFFUSING CAPACITY; RETROSPECTIVE STUDIES; SURVIVAL RATE; TOTAL LUNG CAPACITY; UNITED STATES;

EID: 84966714483     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-016-9896-x     Document Type: Article

References (25)

1. Sontheimer RD (2002) Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 46(4):626–636
2. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus (2002) Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165(2):277–304
3. Fathi M et al (2004) Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 63(3):297–301
4. Fathi M, Lundberg IE, Tornling G (2007) Pulmonary complications of polymyositis and dermatomyositis. Semin Respir Crit Care Med 28(4):451–458
5. Labirua A, Lundberg IE (2010) Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. Curr Opin Rheumatol 22(6):633–638
6. Mimori, T., R. Nakashima, and Y. Hosono, Interstitial Lung Disease in Myositis: Clinical Subsets, Biomarkers, and Treatment. Curr Rheumatol Rep, 2012
7. Solomon J, Swigris JJ, Brown KK (2011) Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol 37(1):100–109
8. Torres C et al (2006) Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity 39(3):205–215
9. Danko K et al (2004) Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore) 83(1):35–42
10. Kalluri M, Oddis CV (2010) Pulmonary manifestations of the idiopathic inflammatory myopathies. Clin Chest Med 31(3):501–512
11. Marie I et al (2002) Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 47(6):614–622
12. Takada K, Nagasaka K, Miyasaka N (2005) Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 38(5):383–392
13. Moghadam-Kia S, et al (2015) Anti-MDA5 is associated with rapidly progressive lung disease and poor survival in U.S. patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res 68(5):689–694
14. Woo JH et al (2013) Mortality factors in idiopathic inflammatory myopathy: focusing on malignancy and interstitial lung disease. Mod Rheumatol 23(3):503–508
15. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292(8):403–407
16. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292(7):344–347
17. Macintyre N et al (2005) Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 26(4):720–735
18. Miller MR et al (2005) General considerations for lung function testing. Eur Respir J 26(1):153–161
19. Grau JM et al (1996) Interstitial lung disease related to dermatomyositis. Comparative study with patients without lung involvement. J Rheumatol 23(11):1921–1926
20. Douglas WW et al (2001) Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 164(7):1182–1185
21. Kang EH et al (2005) Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford) 44(10):1282–1286
22. Marie I et al (2001) Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol 28(10):2230–2237
23. Johnson C et al (2014) Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type. Respir Med 108(10):1542–1548
24. Fujisawa T et al (2014) Prognostic factors for myositis-associated interstitial lung disease. PLoS one 9(6):e98824
25. Danieli MG et al (2014) Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study. Autoimmun Rev 13(10):1048–1054